Supernus Q4 total revenues hit USD 211.6 million, up 21%

Reuters02-25
Supernus Q4 total revenues hit USD 211.6 million, up 21%

Supernus reported Q4 FY2025 total revenues of USD 211.6 million (+21%) and FY2025 total revenues of USD 719.0 million (+9%). Q4 net product sales were USD 158.1 million (-5%) and collaboration revenue from ZURZUVAE was USD 32.8 million (no prior-period comparison provided). Q4 operating loss was USD 4.0 million, while FY2025 operating loss was USD 62.3 million; Q4 net loss was USD 4.1 million (diluted loss per share: USD 0.07) and FY2025 net loss was USD 38.6 million (diluted loss per share: USD 0.68). Cash, cash equivalents and current marketable securities were USD 308.7 million at Dec. 31, 2025. In commercial updates, Supernus said new patient initiation for ONAPGO resumed in Q1 2026 after progress securing additional supply; a second supplier is expected to begin supplying ONAPGO in 2027. ONAPGO Q4 FY2025 net product sales were USD 8.9 million following the U.S. launch in April 2025, and the company said more than 1,800 enrollment forms have been submitted by over 540 prescribers since launch. Q4 FY2025 net sales were USD 81.0 million for Qelbree (+9%) and USD 38.6 million for GOCOVRI (+5%). Supernus also recognized USD 15.0 million of licensing revenue in Q4 FY2025 tied to a regulatory milestone under its collaboration agreement with Shionogi. For FY2026, Supernus guided for total revenues of USD 840 million to USD 870 million, operating earnings of USD 0 million to USD 30 million, and adjusted operating earnings of USD 140 million to USD 170 million, including ONAPGO net sales of USD 45 million to USD 70 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Supernus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602241605PRIMZONEFULLFEED9660530) on February 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment